• Teknova to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023

    Source: Nasdaq GlobeNewswire / 23 Feb 2023 08:00:02   America/New_York

    HOLLISTER, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2022, on Wednesday, March 15, 2023, following the close of market.

    Teknova will host a webcast and conference call on Wednesday, March 15, 2023, beginning at 5:00 p.m. ET. Participants can access the live webcast on the Investor Relations section of the Teknova website and at this link: https://edge.media-server.com/mmc/p/6iefisfj. To receive a PIN number for dial in, participants can register for the webcast via this link: https://register.vevent.com/register/BI0f355397c6884c52ab3ec2b25cfbaea9. The webcast will be available for replay on the Company’s website approximately two hours after the event.

    About Teknova   
    Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel therapies that will help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in cell and gene therapy, molecular diagnostics, and synthetic biology. Our fast turnaround of high-quality agar plates, microbial culture media, buffers and reagents, and water helps our customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 200,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by our team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of novel therapies.


    Investor Contacts 
Matt Lowell 
Chief Financial Officer 
matt.lowell@teknova.com
+1 831-637-1100 

Sara Michelmore 
MacDougall Advisors 
smichelmore@macdougall.bio 
+1 781-235-3060 

Media Contact 
Jennifer Henry  
Senior Vice President, Marketing 
jenn.henry@teknova.com  
+1 831-313-1259 

    Primary Logo

Share on,